News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Pharma Partnering Dollars Continue to Decline for Biotech, Burrill & Company Reports

8/1/2012 10:24:22 AM

SAN FRANCISCO, CA--(Marketwire - August 01, 2012) -

The $3.4 billion partnering agreement announced in July between Bristol-Myers Squibb and AstraZeneca to share Amylin profits points to a troubling trend in partnering deals for new drugs, diagnostics, and tools in development, Burrill & Company reports. Once a reliable source of funding for development activities, biotech companies are facing increasing competition for partnering dollars at a time when there's a shrinking pool of spending.

This year, partnering deals for therapeutics, diagnostics, and tools companies during the first seven months totaled $18.9 billion, below the $22.7 billion for the same period a year ago. The decline continues a multi-year slide for partnering activity since at least 2009. Were partnering activity to continue at its current pace, it would total $32.3 billion this year, compared to $52.8 billion in 2009.

Partnering activity has become increasingly concentrated, with the top ten deals accounting for more than half of the $18.9 billion in transactions so far this year, with the top deal -- between Bristol-Myers and AstraZeneca -- not involving biotechs at all. In addition, a pickup in pharmaceutical partnerships with academic and non-profit institutions -- more than a dozen were announced in July -- is drawing funding and energy away from traditional partnerships with biotech companies.

"Growing competition with academics and non-profits, reorganized pipelines, and financial pressures on Big Pharma budgets are squeezing the partnering dollars going to biotechs," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences. "The difficult financing environment is leaving biotechs in a weak position at the negotiating table."

Even though overall deal size is down, exclusive of royalties, upfront payments for deals in which values were disclosed have risen slightly to an average of $27.6 million, from $25.6 million in 2011. That, however, is still below the $29 million average seen in 2010.

Therapeutic Parntering Deals Through the First Seven Months 2011 vs. 2012   
By Stage of   Discovery/  Phase 1       Phase 2       Phase 3/    Marketed  
 Asset for    Preclinical                             Pre-                  
 deals with                                           approval              
               2011  2012    2011  2012    2011  2012  2011  2012  2011 2012
Total Deals      18    12       6     6       7     5    12     7    10   10
Total Deal                                                                  
 Values        6674  3119    1655  1533    1942  1632  3969  2397  1402  740
Average Deal                                                                
 Value        370.8 259.9   275.8 255.5   277.4 326.4 330.8 342.4 140.2 74.0
Total Upfront                                                               
 Values         206   266     113   102     191   189   800   318   269  379
 Value         11.4  22.2    18.8  17.0    27.3  37.8  66.7  45.4  26.9 37.9

Two life sciences companies completed IPOs in July. Durata Therapeutics, which is developing drugs to treat infectious disease, raised $77.6 million. Hyperion Therapeutics, which is developing drugs for orphan diseases and hepatology, raised $50 million. Both companies priced their offerings below their target range and sold more shares than they had expected to sell in order to raise what they did. Nevertheless, life sciences companies that have gone public in 2012 are up 19.8 percent as a group, beating the broader market indices.

"The relatively strong performance of these new issues is a signal that companies that brave the IPO market are becoming aligned with investors on their value," says Burrill. "It also reflects that these companies, as a whole, are making progress in their businesses."

Biotech stocks in July outperformed the general market. The major indices managed to stay in positive territory despite recurring concerns about the European debt crisis and the weakness in the U.S. economy. For the month, the Burrill Biotech Select posted a 4.4 percent gain, compared to 1 percent for the Dow Jones Industrial Average and a .2 increase in the Nasdaq Composite Index.

Burrill Indices                                                             
BURRILL INDICES                                               Month   Year  
                              12/30/2011 6/29/2012 7/31/2012  Change  Change
Burrill Select                    432.49    539.55    563.53   4.40%  30.30%
Burrill Large Cap                 529.22    657.96    680.02   3.40%  28.50%
Burrill Mid-Cap                   295.33    358.25    349.21  -2.50%  18.20%
Burrill Small Cap                  82.75    101.56    101.27  -0.30%  22.40%
Burrill Diagnostics               175.42    196.13    184.28  -6.00%   5.10%
Burrill Personalized Medicine     100.62    111.37    111.45   0.10%  10.80%
Burrill Biogreentech              149.36    155.42    155.86   0.30%   4.40%
NASDAQ                           2605.15   2935.05   2939.52   0.20%  12.80%
DJIA                            12217.56  12880.09  13008.68   1.00%   6.50%
S&P 500                           1257.6   1362.16   1379.32   1.30%   9.70%
Amex Biotech                     1091.42   1469.21   1487.01   1.20%  36.20%
Amex Pharmaceutical               332.94    348.08    360.17   3.50%   8.20%

After three-months of wrangling, GlaxoSmithKline reached an agreement to acquire Human Genome Sciences for $3.6 billion, the largest M&A transaction for the month. GSK raised its all-cash offer to $14.25 from the $13 it offered in April to close the deal. The acquisition gives GSK full control of Benlysta, its jointly-owned drug for the treatment of lupus and expands the drug giant's portfolio to include experimental drugs for the treatment of diabetes and heart disease. The final price represents a 99 percent premium over Human Genome Sciences closing price on April 17, the day before GSK's bid for the company became public. Overall, M&A activity in 2012 continues to lag the pace of dealmaking a year ago with global activity down 38.1 percent year-to-date.

On the venture capital front, financings in July fell to $983 million, down from $1.3 billion in June. Overall, venture funding for the life sciences (including therapeutics, diagnostics, tools and technology, industrial and agricultural biotechnology, medical devices, digital health, and health IT), continues to outpace the levels seen in 2011, and is up 24 percent year-to-date.

Life Sciences Scorecard in USD M                                            
                                              YTD July    YTD July          
                                              31, 2012    31, 2011    Change
Global Venture Capital                        7,242       5,809        24.7%
U.S. VC                                       5,438       4,355        24.9%
IPOs (21 in 2012 v. 35 in 2011)               1,498       3,241       -53.8%
U.S. IPOs (11 in 2012 v. 13 in 2011)          758         1,111       -31.8%
Global PIPEs                                  3,696       2,400        54.0%
U.S. PIPEs                                    947         1,052       -10.0%
Global Follow-ons                             4,202       7,673       -45.2%
U.S. Follow-ons                               3,703       4,051        -8.6%
Global Other Equity                           955         482          98.3%
U.S. Other Equity                             929         198         370.4%
Global Debt Offerings                         14,037      29,004      -51.6%
U.S. Debt                                     9,734       15,484      -37.1%
Global Other Debt                             12,481      9,119        36.9%
U.S. Other Debt                               11,056      3,511       214.9%
Total Global Public Financings                36,869      51,919      -29.0%
Total U.S. Public Financings                  27,127      25,406        6.8%
Global Partnering                             19,585      22,825      -14.2%
U.S. Partner/Licenser                         12,130      14,478      -16.2%
Global M&A                                    78,191      126,311     -38.1%
M&A, U.S. Target                              57,296      67,752      -15.4%

*Includes therapeutics, diagnostics,tools and technology, medical devices and technology, digital health, healthcare IT, industrial and agricultural biotechnology

July brought a crop of new drug approvals from the U.S. Food and Drug Administration. This included Onyx Pharmaceuticals' accelerated approval of its multiple myeloma drug Kyprolis based on mid-stage clinical trial data, Vivus' diet drug Qysimia, Amarin's cholesterol-reducing drug Vascepa, and Forest Lab's Tudorza Pressair inhaler to treat chronic obstructive pulmonary disease. Overall, the pace of new drug approvals year-to-date is lagging slightly behind the pace of 2011 with a total of 19 new drugs and biologics approved so far in 2012 compared to 21 during the same period a year ago.

In the wake of the U.S. Supreme Court's decision that upheld most of the Patient Protection and Affordable Care Act, the House made repeated efforts to dismantle the legislation. The House also voted to keep funding for the National Institutes of Health flat for 2013 at $30.6 billion. Though the flat budget is a concern for advocates of biomedical research, there are growing worries about automatic across-the-board budget cuts put into place last year if Congressional representatives fail to agree on reductions to the federal deficit.

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit:

Daniel Levine
Managing Director
Burrill & Company
Email Contact

Digg this    Bookmark with    Add to Newsvine


Read at

comments powered by Disqus